Document is current
Any future updates will be listed below
-
Authors
Silverstein, Steven M. https://orcid.org/0000-0002-8243-2485
Oddone, Francesco https://orcid.org/0000-0002-2504-0004
Kolko, Miriam https://orcid.org/0000-0001-8697-0734
Brinkmann, Christian K.
Christie, William C.
Bicket, Amanda K. https://orcid.org/0000-0001-6147-3504
Gous, Petrus N. J.
Luebke, Jan https://orcid.org/0000-0002-3946-5759
Maram, Jyotsna https://orcid.org/0000-0001-8727-0692
Nguyen, Ashley https://orcid.org/0009-0002-5362-0708
Craven, E. Randy https://orcid.org/0000-0002-2077-659X
Pu, Yongjia
Jiao, Jenny
Bejanian, Marina
Robinson, Michael R.
,
Bercovich, Gabriel
Gentile, Carolina
Lerner, Simon Fabian
Lupinacci, Anahi
Santos, Rodrigo
Zeolite, Carlos Ignacio
Kerr, Nathan
Anguelov, Botio
Daskalov, Veselin
Dzhelebov, Dimitar
Grupcheva, Christina
Hristozov, Valentin
Ivanova, Stanislava
Misheva, Aneta
Penkov, Milen
Topchiyska, Malina
Yanev, Petar
Fichtl, Marek
Brinkmann, Christian
Lubke, Jan
Schargus, Marc
van Oterendorp, Christian
Pavicic-Astalos, Jasna
Cagini, Carlo
Milano, Giovanni
Scorcia, Vincenzo
Vingolo, Enzo M.
Wells, Tony
Cisiecki, Slawomir
Raczynska, Dorota
Teper, Slawomir
Zalewski, Dominik
Gous, Petrus
Helsdingen, Nicolaas van
Alaghband, Pouya
Bourne, Rupert
Cheeseman, Robert
Dubois, Vincent
Hopes, Marina
Lascaratos, Gerassimos
Levin, Samantha
Ansari, Husam
Basha, Mahdi
Berdahl, John
Bettis, Daniel
Bicket, Amanda
Blasberg, Robert
Caldwell, Delmar
Cantor, Louis
Christie, William
Duzman, Eran
Elfervig, John
Evans, Richard
Gupta, Shailesh
Gutmark, Ron
Hendrix, Jason
Jerkins, Gary
Jorgensen, Adam
Kammer, Jeffrey
Khaimi, Mahmoud
Kubal, Aarup
Lind, John
Logan, Dwayne
Martin, Elizabeth
Moroi, Sayoko
Moster, Marlene
Moyes, Andrew
Nolan, Daniel
Paauw, James
Park, Abraham
Patel, Hemang
Paul, Matthew
Perez, Bernard
Sarkisian, Steven Jr
Segal, Bruce
Shah, Manjool
Silverstein, Steven
Sims, Annette
Slabaugh, Mark
Wallace, Dana
Walman, Gerald
Walters, Thomas
Wirta, David
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03850782 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON)
https://doi.org/10.1007/s40265-025-02154-4
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Accepted: 27 January 2025
First Online: 22 February 2025
Declarations
:
: Allergan (prior to its acquisition by AbbVie) and/or AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication.
: Amanda K. Bicket is a consultant for W.L. Gore and Associates, Inc. Christian Brinkmann has received financial compensation from AbbVie, Afidera, Appelis, Bayer, Heidelberg Engineering, Novartis, Santen, Teleon Surgical, and Théa Laboratories. William C. Christie is a consultant for Allergan (an AbbVie company). Petrus N.J. Gous has no financial interests to disclose. Miriam Kolko is a speaker for AbbVie, Santen, Théa Laboratories, and Topcon; and sits on advisory boards for AbbVie, Santen, and Théa Laboratories. Jan Luebke is a speaker for AbbVie, Alcon, Glaukos, iStar Medical, Santen, and Théa Laboratories and sits on advisory boards for AbbVie and Santen. Francesco Oddone is a speaker for AbbVie, Omikron Italia, Santen, Sifi, and Theà; sits on advisory boards for AbbVie, Dompè, and Santen; and has received research grants from AbbVie, Santen, and Omikron Italia. Steven M. Silverstein has no disclosures beyond participation in this clinical study. Marina Bejanian, E. Randy Craven, Jenny Jiao, Jyotsna Maram, Ashley Nguyen, Yongjia Pu, and Michael R. Robinson are employees of AbbVie and may hold AbbVie stock.
: Institutional review board or independent ethics committee approval was obtained at each site before the study began, and the study was performed in compliance with Good Clinical Practice, the principles of the Declaration of Helsinki, and applicable laws and regulations (ClinicalTrials.gov registration number NCT03850782).
: All patients in this study provided written informed consent before undergoing any study-related procedure.
: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent, scientific research and will be provided following review and approval of a research proposal, statistical analysis plan (SAP), and execution of a data sharing agreement (DSA). Data requests can be submitted at any time after approval in the USA and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link: .
: Not applicable.
: Study design: M.B. and A.N.; data collection: A.K.B., C.K.B., W.C.C., P.N.J.G., J.L., M.K., F.O., and S.M.S.; statistical analysis: J.J. and Y.P.; data interpretation: M.B., A.K.B., C.K.B., W.C.C., P.N.J.G., J.J., J.L., M.K., J.M., A.N., F.O., Y.P., and S.M.S.; drafting, revision, and approval of the manuscript: M.B., A.K.B., C.K.B., W.C.C., P.N.J.G., J.J., J.L., M.K., J.M., A.N., F.O., Y.P., and S.M.S.
